Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer

Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker

(2021) Fernanda G. Kugeratski et al.   NATURE CELL BIOLOGY

The biology, function, and biomedical applications of exosomes

(2020) Raghu Kalluri et al.   SCIENCE

Endocytosis of Extracellular Vesicles and Release of Their Cargo from Endosomes

(2020) Bhagyashree S. Joshi et al.   ACS Nano

Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

(2020) Andrew V. Anzalone et al.   NATURE BIOTECHNOLOGY

RAS-targeted therapies: is the undruggable drugged?

(2020) Amanda R. Moore et al.   NATURE REVIEWS DRUG DISCOVERY

Advancements and Obstacles of CRISPR-Cas9 technology in Translational Research

(2019) Liting You et al.   Molecular Therapy-Methods & Clinical Development

Identification of preexisting adaptive immunity to Cas9 proteins in humans

(2019) Carsten T. Charlesworth et al.   NATURE MEDICINE

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

(2019) Danny Wilbie et al.   ACCOUNTS OF CHEMICAL RESEARCH

Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy

(2019) Tuying Yong et al.   Nature Communications

Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities

(2018) Ling Li et al.   BIOMATERIALS

Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs

(2018) Yao Lin et al.   Advanced Science

Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population

(2018) Vijaya L. Simhadri et al.   Molecular Therapy-Methods & Clinical Development

High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population

(2018) Dimitrios L. Wagner et al.   NATURE MEDICINE

Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting

(2017) Seung Min Kim et al.   JOURNAL OF CONTROLLED RELEASE

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

(2017) Sushrut Kamerkar et al.   NATURE

Delivery technologies for genome editing

(2017) Hao Yin et al.   NATURE REVIEWS DRUG DISCOVERY

Survival of pancreatic cancer cells lacking KRAS function

(2017) Mandar Deepak Muzumdar et al.   Nature Communications

CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein into Cultured Cells and Single-Cell Embryos

(2016) Evguenia Kouranova et al.   HUMAN GENE THERAPY

Engineering Delivery Vehicles for Genome Editing

(2016) Christopher E. Nelson et al.   Annual Review of Chemical and Biomolecular Engineering

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

(2015) Xiaofeng Zheng et al.   NATURE

Therapeutic genome editing: prospects and challenges

(2015) David Benjamin Turitz Cox et al.   NATURE MEDICINE

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

Improving CRISPR-Cas nuclease specificity using truncated guide RNAs

(2014) Yanfang Fu et al.   NATURE BIOTECHNOLOGY

KRAS: feeding pancreatic cancer proliferation

(2014) Kirsten L. Bryant et al.   TRENDS IN BIOCHEMICAL SCIENCES

Roles for KRAS in Pancreatic Tumor Development and Progression

(2013) Marina Pasca di Magliano et al.   GASTROENTEROLOGY

Genome engineering using the CRISPR-Cas9 system

(2013) F Ann Ran et al.   Nature Protocols

Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy

(2013) Vedell Louis Jeune et al.   Human Gene Therapy Methods

Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal Models

(2011) Kleopatra Rapti et al.   MOLECULAR THERAPY

Effect of Genome Size on AAV Vector Packaging

(2009) Zhijian Wu et al.   MOLECULAR THERAPY